Meeting
2017 Genitourinary Cancers Symposium
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
Authors
David F. McDermott
Beth Israel Deaconess Medical Center, Boston, MA
David F. McDermott , Michael B. Atkins , Robert J. Motzer , Brian I. Rini , Bernard J. Escudier , Lawrence Fong , Richard Wayne Joseph , Sumanta K. Pal , Mario Sznol , John D. Hainsworth , Walter Michael Stadler , Thomas E. Hutson , Alain Ravaud , Sergio Bracarda , Cristina Suarez , Toni K. Choueiri , YounJeong Choi , Mahrukh A. Huseni , Gregg Daniel Fine , Thomas Powles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01984242
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 431)
DOI
10.1200/JCO.2017.35.6_suppl.431
Abstract #
431
Poster Bd #
B14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
First Author: Rita Migliorino
Poster
2019 ASCO Annual Meeting
Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
First Author: Brian I. Rini
Poster
2022 ASCO Annual Meeting
Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
First Author: Maria Cortes
Poster
2019 ASCO Annual Meeting
Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).
First Author: Sumanta K. Pal